Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Jan 30;14:875–888. doi: 10.2147/IJN.S186225

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 Wang et al. This work is published and licensed by Dove Medical Press Limited

The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

Evaluation of the effect of DATS-MIONs on myocardial protection.

Notes: (A) Proliferation of embryonic cardiomyocyte H9C2 cells incubated with different concentrations of DATS-MIONs as monitored on a real-time cell analyzer. (B) TUNEL assay of myocardial tissues harvested from treated (iron oxide, top) and untreated (control, bottom) mice with IR-induced heart injury. Apoptotic cells were stained positive in the assay and highlighted by the red fluorescence that they emitted. (C) Representative echocardiograms of a mouse with MI in which DATS-MIONs were injected and a mouse with MI as a control that did not receive any treatment. (D) Column charts comparing the heart rate, ejection fraction, and fraction shortening of the three abovementioned murine models. Bars represent standard error of mean. *P<0.05.

Abbreviations: DATS, diallyl trisulfide; IR, ischemia–reperfusion; MI, myocardial infarction; MIONs, mesoporous iron oxide nanoparticles.

Evaluation of the effect of DATS-MIONs on myocardial protection.

Notes: (A) Proliferation of embryonic cardiomyocyte H9C2 cells incubated with different concentrations of DATS-MIONs as monitored on a real-time cell analyzer. (B) TUNEL assay of myocardial tissues harvested from treated (iron oxide, top) and untreated (control, bottom) mice with IR-induced heart injury. Apoptotic cells were stained positive in the assay and highlighted by the red fluorescence that they emitted. (C) Representative echocardiograms of a mouse with MI in which DATS-MIONs were injected and a mouse with MI as a control that did not receive any treatment. (D) Column charts comparing the heart rate, ejection fraction, and fraction shortening of the three abovementioned murine models. Bars represent standard error of mean. *P<0.05.

Abbreviations: DATS, diallyl trisulfide; IR, ischemia–reperfusion; MI, myocardial infarction; MIONs, mesoporous iron oxide nanoparticles.